Additional filter size for KadcylaSubscription
The summary of product characteristics for Kadcyla (trastuzumab emtansine; Roche) has been revised to include recommendations on an additional filter size of 0.2 micron for in-line filtration during infusion using sodium chloride 0.9% as a solvent.
Contraindications with Ex-lax Senna PillsSubscription
The summary of product characteristics (SPC) for Ex-lax Senna Pills (sennoside; Novartis) now states that the medicine is contradicted with irritation of the gastrointestinal tract, abdominal pain of unknown origin, severe dehydration states, especially hypokalaemia, and in children aged under 12 years. Patients taking cardiac glycosides, antiarrhythmic medicinal products, medicinal products inducing QT-prolongation, diuretics, adrenocorticosteroids or liquorice root, have to consult ...
Reduced efficacy of benzodiazepines with XenicalSubscription
The summary of product characteristics for Xenical (orlistat; Roche) now states that there are some case reports of reduced efficacy of benzodiazepines coincidental to the initiation of orlistat treatment in previously well controlled patients. Therefore, orlistat treatment should only be initiated after careful consideration of the possible impact in these patients.
New indication for EyleaSubscription
Eylea (aflibercept; Bayer) is now indicated for visual impairment due to myopic choroidal neovascularisation. Further changes to the summary of product characteristics reflect this addition.
AWMSG November medicines approvalsSubscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial ...
New requirements for controlled drugsSubscription
The Home Office has highlighted two changes affecting controlled drugs. First, from 30 November 2015, amendments to the Misuse of Drugs Regulations 2001 will make the use of an approved form for the requisitioning of Schedule 2 and 3 Controlled Drugs in the community mandatory. This applies to both requisitions for human and for veterinary use.
November 2015: SMC decisionsSubscription
The Scottish Medicines Consortium has accepted the following medicines for use in NHS Scotland: atazanavir and cobicistat (Evotaz; Bristol-Myers Squibb); edoxaban (Lixiana; Daiichi Sankyo), for two separate indications; pembrolizumab (Keytruda; Merck Sharp and Dohme), as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab; tiotropium/olodaterol (Spiolto Respimat; Boehringer Ingelheim); and triamcinolone hexacetonide ...
Errors in the BNF for ChildrenSubscription
An error has been found in the new British National Formulary (BNF) for Children (2015–2016) regarding the indications of aciclovir. Some indications are omitted or are unclear.
Non-medical prescribers websiteSubscription
A new website called Prescribers SPaCE – Sharing Practice and Continuing Education – has been launched for non medical prescribers (NMPs) by the University Hospitals Birmingham NHS Foundation Trust and others. The website is intended to provide a forum for NMPs to to share ideas, evidence-based resources and good practice tools.
Covert administration in care homes flowchartSubscription
Aneurin Bevan University Health Board in Wales and the Cardiff School of Pharmacy and Pharmaceutical Sciences have developed a flowchart to inform decision making in care homes related to covert administration. The flowchart supports care home staff to differentiate between difficult to swallow and covert administration, and provides guidance for subsequent steps such as informing the multidisciplinary team and assessing residents for capacity.
How to use the BNFSubscription
The Centre for Pharmacy Postgraduate Education (CPPE) has launched a new distance e-learning programme called ‘How to use the BNF’. The programme explores the recent changes in the structure of content in the British National Formulary (BNF). The programme can be accessed on the CPPE website.
Sexual health learning programmeSubscription
The Centre for Pharmacy Postgraduate Education (CPPE) has launched a new e-learning module called ‘Sexual health in pharmacies’. It is designed to help pharmacists and their teams deliver sexual health services. This programme replaces the ‘Sexual health in pharmacies: developing your service’ distance learning programme. The new programme can be accessed via ...
The charity Antibiotic Research UK is running a large fundraising and educational event, called the Great British Tea Party, to coincide with European Antibiotic Awareness Day on 18 November 2015. The charity will be providing organisers with information and materials about appropriate and inappropriate antibiotic use. Those ...
The European Medicines Agency (EMA) has released for public consultation a new strategy on antimicrobial resistance addressing medicinal products for veterinary use. The consultation documents can be accessed on the
The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend dinutuximab (when used in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and isotretinoin) as a treatment for high-risk neuroblastoma for children and young people between the ages of 12 months and 17 years.
Controlled drugs consultationSubscription
The National Institute for Health and Care Excellence (NICE) has published a consultation on the safe use and management of controlled drugs. The consultation covers guidance on prescribing, obtaining and supplying, administering, handling, and recording and monitoring use of controlled drugs. It is available ...
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending abatacept (Orencia; Bristol-Myers Squibb), adalimumab (Humira; AbbVie), etanercept (Enbrel; Pfizer) and tocilizumab (RoActemra; Roche) as options for treating juvenile idiopathic arthritis. A consultation on the guidance, which is available from ...